146 related articles for article (PubMed ID: 28977808)
21. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic enzyme pharmacotherapy.
Ferrone M; Raimondo M; Scolapio JS
Pharmacotherapy; 2007 Jun; 27(6):910-20. PubMed ID: 17542772
[TBL] [Abstract][Full Text] [Related]
23. Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice.
Nishiyama H; Nagai T; Kudo M; Okazaki Y; Azuma Y; Watanabe T; Goto S; Ogata H; Sakurai T
Biochem Biophys Res Commun; 2018 Jan; 495(1):273-279. PubMed ID: 29106956
[TBL] [Abstract][Full Text] [Related]
24. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study.
Kahl S; Schütte K; Glasbrenner B; Mayerle J; Simon P; Henniges F; Sander-Struckmeier S; Lerch MM; Malfertheiner P
JOP; 2014 Mar; 15(2):165-74. PubMed ID: 24618443
[TBL] [Abstract][Full Text] [Related]
25. [Experience with the use of 13C-breath test for the evaluation of the efficacy of enzyme substitution therapy with microencapsulated pancreatinin in patients with severe primary pancreatic insufficiency].
Rapoport SI; Maev IV; Kucheriavyĭ IuA; Shubina NA; Semenova NV; Stukova NIu; Archakov AI
Klin Med (Mosk); 2009; 87(1):53-7. PubMed ID: 19256262
[TBL] [Abstract][Full Text] [Related]
26. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study.
Saito T; Hirano K; Isayama H; Nakai Y; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Hamada T; Takahara N; Uchino R; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Pancreas; 2017 Mar; 46(3):341-346. PubMed ID: 28099252
[TBL] [Abstract][Full Text] [Related]
27. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.
Domínguez-Muñoz JE; Nieto-Garcia L; López-Díaz J; Lariño-Noia J; Abdulkader I; Iglesias-Garcia J
BMC Cancer; 2018 May; 18(1):534. PubMed ID: 29728096
[TBL] [Abstract][Full Text] [Related]
28. Exocrine pancreatic insufficiency following esophagectomy.
Huddy JR; Macharg FM; Lawn AM; Preston SR
Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
[TBL] [Abstract][Full Text] [Related]
29. Long-term experience with ZENPEP in infants with exocrine pancreatic insufficiency associated with cystic fibrosis.
Wooldridge JL; Schaeffer D; Jacobs D; Thieroff-Ekerdt R
J Pediatr Gastroenterol Nutr; 2014 Nov; 59(5):612-5. PubMed ID: 25050848
[TBL] [Abstract][Full Text] [Related]
30. Digestive Enzyme Replacement Therapy: Pancreatic Enzymes and Lactase.
Felicilda-Reynaldo RF; Kenneally M
Medsurg Nurs; 2016; 25(3):182-5. PubMed ID: 27522847
[TBL] [Abstract][Full Text] [Related]
31. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
[TBL] [Abstract][Full Text] [Related]
32. Novel ciliate lipases for enzyme replacement during exocrine pancreatic insufficiency.
Brock A; Aldag I; Edskes S; Hartmann M; Herzog T; Uhl W; Schnekenburger J
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1305-12. PubMed ID: 27518039
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic enzyme replacement therapy after gastric resection: An update.
Antonini F; Crippa S; Falconi M; Macarri G; Pezzilli R
Dig Liver Dis; 2018 Jan; 50(1):1-5. PubMed ID: 29170072
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic enzyme replacement therapy following surgery for pancreatic cancer: An exploration of patient self-management.
Dunleavy L; Al-Mukhtar A; Halliday V
Clin Nutr ESPEN; 2018 Aug; 26():97-103. PubMed ID: 29908691
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of stool collections to measure efficacy of PERT in subjects with exocrine pancreatic insufficiency.
Caras S; Boyd D; Zipfel L; Sander-Struckmeier S
J Pediatr Gastroenterol Nutr; 2011 Dec; 53(6):634-40. PubMed ID: 21681115
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic enzyme products: digesting the changes.
Giuliano CA; Dehoorne-Smith ML; Kale-Pradhan PB
Ann Pharmacother; 2011 May; 45(5):658-66. PubMed ID: 21540403
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic enzyme replacement therapy in chronic pancreatitis.
Sikkens EC; Cahen DL; Kuipers EJ; Bruno MJ
Best Pract Res Clin Gastroenterol; 2010 Jun; 24(3):337-47. PubMed ID: 20510833
[TBL] [Abstract][Full Text] [Related]
39. Dependence of PERT endpoint on endogenous lipase activity.
Gao WY; Mulberg AE
Pancreas; 2014 Nov; 43(8):1232-8. PubMed ID: 25102439
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.
Sander-Struckmeier S; Beckmann K; Janssen-van Solingen G; Pollack P
Pancreas; 2013 Aug; 42(6):983-9. PubMed ID: 23587850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
